Literature DB >> 31373367

Spinal Cord Ependymomas With MYCN Amplification Show Aggressive Clinical Behavior.

Amy A Swanson1, Aditya Raghunathan1, Robert B Jenkins1, Martina Messing-Jünger2, Torsten Pietsch3, Michelle J Clarke4, Timothy J Kaufmann5, Caterina Giannini1.   

Abstract

Adult spinal cord ependymomas are typically low grade and have a relatively favorable clinical course following gross total resection. We report 4 cases of anaplastic spinal cord ependymoma with MYCN amplification, an exceptionally rare finding. All cases occurred in the spinal cord of adolescent and young adult women and had morphological and immunohistochemical features of anaplastic ependymomas (World Health Organization grade III). Chromosomal microarray analysis demonstrated amplification of 2p24 (including MYCN) in all cases. One patient died 6 months after surgery. Another patient recently had removal of metastatic nodules in the thoracic region, following gross total resection and adjuvant radiation therapy of a lumbar ependymoma 1 year previously. One patient responded well after chemotherapy but died after multiple relapses 82 months after diagnosis. We found MYCN amplification reported in 2 other ependymomas, both anaplastic and arising in the spinal cord of adult females (Brain Pathol 2001;11:133-43). One patient had multiple recurrences in the spinal cord and an intracranial metastasis. Although MYCN amplification is rare in ependymomas, the current and previously reported cases suggest that this is associated with higher-grade histology, spinal location, and often unfavorable prognosis. The clinical significance and therapeutic implications of MYCN amplification in ependymomas require further evaluation.
© 2019 American Association of Neuropathologists, Inc. All rights reserved.

Entities:  

Keywords:  Anaplastic ependymoma; Ependymoma; MYCN amplification; Spinal cord

Year:  2019        PMID: 31373367     DOI: 10.1093/jnen/nlz064

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  19 in total

Review 1.  Major Features of the 2021 WHO Classification of CNS Tumors.

Authors:  Heather L Smith; Nitin Wadhwani; Craig Horbinski
Journal:  Neurotherapeutics       Date:  2022-05-16       Impact factor: 7.620

Review 2.  2021 WHO classification of tumours of the central nervous system: a review for the neuroradiologist.

Authors:  Cillian McNamara; Kshitij Mankad; Stefanie Thust; Luke Dixon; Clara Limback-Stanic; Felice D'Arco; Thomas S Jacques; Ulrike Löbel
Journal:  Neuroradiology       Date:  2022-07-22       Impact factor: 2.995

3.  Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics.

Authors:  Zhichao Wu; Zied Abdullaev; Drew Pratt; Hye-Jung Chung; Shannon Skarshaug; Valerie Zgonc; Candice Perry; Svetlana Pack; Lola Saidkhodjaeva; Sushma Nagaraj; Manoj Tyagi; Vineela Gangalapudi; Kristin Valdez; Rust Turakulov; Liqiang Xi; Mark Raffeld; Antonios Papanicolau-Sengos; Kayla O'Donnell; Michael Newford; Mark R Gilbert; Felix Sahm; Abigail K Suwala; Andreas von Deimling; Yasin Mamatjan; Shirin Karimi; Farshad Nassiri; Gelareh Zadeh; Eytan Ruppin; Martha Quezado; Kenneth Aldape
Journal:  Neuro Oncol       Date:  2022-04-01       Impact factor: 13.029

Review 4.  Updates in the classification of ependymal neoplasms: The 2021 WHO Classification and beyond.

Authors:  Catena Kresbach; Sina Neyazi; Ulrich Schüller
Journal:  Brain Pathol       Date:  2022-03-21       Impact factor: 7.611

5.  Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study.

Authors:  Jonas E Adolph; Gudrun Fleischhack; Ruth Mikasch; Julia Zeller; Monika Warmuth-Metz; Brigitte Bison; Martin Mynarek; Stefan Rutkowski; Ulrich Schüller; Katja von Hoff; Denise Obrecht; Torsten Pietsch; Stefan M Pfister; Kristian W Pajtler; Olaf Witt; Hendrik Witt; Rolf-Dieter Kortmann; Beate Timmermann; Jürgen Krauß; Michael C Frühwald; Andreas Faldum; Robert Kwiecien; Udo Bode; Stephan Tippelt
Journal:  Neuro Oncol       Date:  2021-06-01       Impact factor: 12.300

Review 6.  Ependymoma: Evaluation and Management Updates.

Authors:  Roberta Rudà; Francesco Bruno; Alessia Pellerino; Riccardo Soffietti
Journal:  Curr Oncol Rep       Date:  2022-04-06       Impact factor: 5.945

Review 7.  cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors.

Authors:  David W Ellison; Kenneth D Aldape; David Capper; Maryam Fouladi; Mark R Gilbert; Richard J Gilbertson; Cynthia Hawkins; Thomas E Merchant; Kristian Pajtler; Sriram Venneti; David N Louis
Journal:  Brain Pathol       Date:  2020-06-23       Impact factor: 7.611

8.  High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma.

Authors:  Mark Raffeld; Zied Abdullaev; Svetlana D Pack; Liqiang Xi; Sushma Nagaraj; Nicole Briceno; Elizabeth Vera; Stefania Pittaluga; Osorio Lopes Abath Neto; Martha Quezado; Kenneth Aldape; Terri S Armstrong; Mark R Gilbert
Journal:  Acta Neuropathol Commun       Date:  2020-07-08       Impact factor: 7.801

9.  Pediatric spinal intramedullary anaplastic myxopapillary ependymoma: a case report.

Authors:  S Joy Trybula; Nitin R Wadhwani; Laila M Mohammad; Sandi K Lam; Alicia C Lenzen; Tord D Alden
Journal:  Childs Nerv Syst       Date:  2021-06-14       Impact factor: 1.475

Review 10.  Case Report: Sellar Ependymomas: A Clinic-Pathological Study and Literature Review.

Authors:  Liyan Zhao; Yining Jiang; Yubo Wang; Yang Bai; Liping Liu; Yunqian Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-08       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.